Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2024 Thalassemia Highlights
27 June 2024 | Virtual Meeting
Presentation summaries of key beta thalassemia abstracts from ASCO & EHA 2024.
Latest in curative therapies and disease-modifying agents
Treatment of patients with severe transfusion-dependent β-thalassemia with CS-101
Lijie Wang CorrectSeq Therapeutics, Shanghai, China
Safety and efficacy of RM-001 in transfusion-dependent β-thalassemia
Yongrong Lai The First Affiliated Hospital of Guangxi Medical University, Nanning, China
Preliminary results from the EdiTHAL trial: reni-cel for transfusion-dependent β-thalassemia
Alexis Thompson Children's Hospital of Philadelphia, Philadelphia, PA, United States
Efficacy and safety of BRL-101 in transfusion-dependent β-thalassemia
Yongrong Lai The First Affiliated Hospital of Guangxi Medical University, Nanning, China
Latest evidence with luspatercept
Analysis of erythropoiesis and iron metabolism in a cohort of β-thalassemia patients treated with luspatercept in the BELIEVE trial
Nicolo Tesio University of Turin, Turin, Italy
Predicting and evaluating response to luspatercept in transfusion-dependent β-thalassemia
Daniele Lello Panzieri University of Milan, Milan, Italy
Exploring the real-life efficacy and safety of luspatercept with a mixed pattern study
Yesim Aydinok Ege University, Izmir, Turkey
Latest evidence with mitapivat
ENERGIZE: a global Phase III study of mitapivat in adults with non–transfusion-dependent thalassemia
Ali T. Taher American University of Beirut Medical Center, Beirut, Lebanon
Improvements in fatigue and 6-minute walk test in adults with non–transfusion-dependent thalassemia from the ENERGIZE trial
Kevin Kuo University Health Network, Toronto, Canada
